Tags : Vector Neurosciences

M&A

MeiraGTx Acquires Vector Neurosciences to Strengthen its Neurology Portfolio

Shots: Vector’s acquisition is an all-stock transaction including its novel P-II drug candidate AAV-GAD evaluated for Parkinson’s Disease The acquisition focuses on developing candidate AAV-GAD and providing novel treatments for neurological disorders AAV-GAD is a gene therapy candidate delivering glutamic acid decarboxylase (GAD) gene, currently in P-II for Parkinson’s Disease and has also received FTD […]Read More